

RESPONSE UNDER 37 C.F.R. § 1.116  
EXPEDITED PROCEDURE – Art Unit 1636  
Attorney Docket No. 54569.8009.US01

**Listing of claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended). A mammalian *in vitro* mRNA decapping system comprising:

- a) a mammalian polysome-free HeLa cell cytoplasmic extract substantially free of polysomes;
- b) a methylated cap analog; and
- c) a cap-labeled mRNA substrate.

2. (currently amended). The mammalian *in vitro* mRNA decapping system of claim 1  
wherein said mammalian HeLa cell cytoplasmic extract is an a HeLa S100 cell  
cytoplasmic extract which comprises a 100,000 x g, 1 hour supernatant from a  
mammalian cell lysate.

3. (currently amended). The mammalian *in vitro* mRNA decapping system of claim 2  
wherein said mammalian HeLa cell cytoplasmic extract is prepared by dialysis of *this  
clear*  
extract containing 10% glycerol.

4. (cancelled). The composition of claim 1 wherein said mammalian cell lysate is  
obtained from a mammalian cell or tissue

RESPONSE UNDER 37 C.F.R. § 1.116  
EXPEDITED PROCEDURE – Art Unit 1636  
Attorney Docket No. 54569.8009.US01

5. (currently amended). The mammalian *in vitro* mRNA decapping system of claim 4  
2 wherein said mammalian cell cytoplasmic extract is a HeLa S100 cell cytoplasmic  
extract which comprises a 100,000 x g, 1 hour supernatant from a HeLa cell lysate.

6. (previously presented). The mammalian *in vitro* mRNA decapping system of claim 1  
wherein said methylated cap analog is <sup>7<sup>me</sup></sup>GpppG or <sup>7<sup>me</sup></sup>GTP.

7. (cancelled). The composition of claim 1 comprising components for additionally  
detecting mRNA deadenylation and degradation.

8. (cancelled). The composition of claim 7 wherein said mammalian cell cytoplasmic  
extract is depleted of activity of proteins that bind polyadenylate

9. (previously presented). The mammalian *in vitro* mRNA decapping system of claim 1  
wherein said cap-labeled mRNA substrate is labeled at the alpha phosphate of the cap.

10. (previously presented). The mammalian *in vitro* mRNA decapping system of claim 1  
wherein said cap-labeled mRNA substrate is labeled at the cap of said cap-labeled  
mRNA substrate by a label selected from the group consisting of a radioactive label, a  
non-radioactive isotopic label, a fluorescent moiety, a visibly-detectable moiety, a  
releasable substrate ~~or~~ a co-factor for a chemical and enzymatic reaction.

11. (previously presented). The mammalian *in vitro* mRNA decapping system of claim 1  
wherein said cap-labeled mRNA substrate comprises poly(A) or at least one RNA  
element.

RESPONSE UNDER 37 C.F.R. § 1.116  
EXPEDITED PROCEDURE – Art Unit 1636  
Attorney Docket No. 54569.8009.US01

12. (previously presented). The mammalian *in vitro* mRNA decapping system of claim

11 wherein said RNA element is an AU-rich element.

13. (previously presented). The mammalian *in vitro* mRNA decapping system of claim

11 wherein said RNA element is a pyrimidine-rich element.

14. (cancelled). A polypeptide which has a molecular weight of about 50 to about 100 kilodaltons (kD) in molecular exclusion chromatography, precipitates with 20% ammonium sulfate, elutes at between about 440 to 500mM NaCl from a heparin-Sepharose column, and decaps mammalian RNA.

15. (cancelled). A polynucleotide which encodes a polypeptide which has a molecular weight of about 50 to about 100 kilodaltons (kD) in molecular exclusion chromatography, precipitates with 20% ammonium sulfate, elutes at between about 440 to 500mM NaCl from a heparin-Sepharose column, and decaps mammalian RNA.

16. (cancelled). An antibody which binds specifically and with high affinity to a polypeptide which has a molecular weight of about 50 to about 100 kilodaltons (kD) in molecular exclusion chromatography, precipitates with 20% ammonium sulfate, elutes at between about 440 to 500mM NaCl from a heparin-Sepharose column, and decaps mammalian RNA.

17. (currently amended). A kit for measuring mRNA decapping *in vitro* comprising:

a) a mammalian polysome-free HeLa cell cytoplasmic extract;

RESPONSE UNDER 37 C.F.R. § 1.116  
EXPEDITED PROCEDURE – Art Unit 1636  
Attorney Docket No. 54569.8009.US01

b) a methylated cap analog; and

c) cap-labeled mRNA substrate.

18. (cancelled).

The kit of claim 17 further comprising a cap-labeled mRNA substrate.

19. (previously presented). The kit of claim 17 wherein said cap-labeled mRNA substrate is labeled at the alpha phosphate of the cap.

20. (previously presented). The kit of claim 17 wherein said cap-labeled mRNA substrate is labeled at the cap of said cap-labeled mRNA substrate by a label selected from the group consisting of a radioactive label, a non-radioactive isotopic label, a fluorescent moiety, a visibly-detectable moiety, a releasable substrate or a co-factor for a chemical and enzymatic reaction.

21. (cancelled).

The kit of claim 17 wherein said mammalian cell cytoplasmic extract is depleted of activity of proteins that bind polyadenylate.

22. (cancelled).

A method for carrying out *in vitro* mammalian mRNA decapping comprising the steps of

a) providing the composition of claim 1.

b) incubating said composition at about 30°C for about 30 min and

monitoring decapping by detection of release of label from said cap-labeled RNA.

RESPONSE UNDER 37 C.F.R. § 1.116  
EXPEDITED PROCEDURE – Art Unit 1636  
Attorney Docket No. 54569.8009.US01

23. (cancelled). A method for identifying a compound as a modulator of mammalian mRNA decapping comprising carrying out the method of claim 22 in the presence and absence of said compound, and correlating any change in decapping by the presence of said compound with modulator activity of said compound.

24. (cancelled). The method of claim 23 wherein said cap-labeled mRNA substrate comprises poly(A) or at least one RNA element.

25. (cancelled). The composition of claim 23 wherein said RNA element is an AU-rich element.

26. (cancelled). The composition of claim 23 wherein said RNA element is a pyrimidine-rich element.

27. (previously presented) The mammalian *in vitro* mRNA decapping system of claim 1  
+ function (112, 6<sup>th</sup> → ok)  
further comprising means for sequestering proteins that bind to poly(A).  
[redacted]

28. (previously presented) The mammalian *in vitro* mRNA decapping system of claim  
11 further comprising means for stimulating decapping of the cap-labeled mRNA  
substrate wherein the cap-labeled mRNA substrate comprises poly (A).

29. (previously presented) The mammalian *in vitro* mRNA decapping system of claim  
11 further comprising a cold poly(A) competitor RNA.

RESPONSE UNDER 37 C.F.R. § 1.116  
EXPEDITED PROCEDURE – Art Unit 1636  
Attorney Docket No. 54569.8009.US01

30. (previously presented) The mammalian *in vitro* mRNA decapping system of claim

+ function

12 further comprising means for reducing decapping of the cap-labeled mRNA



substrate.

31. (currently amended) The mammalian *in vitro* mRNA decapping system of claim

12 further comprising an ARE AU-rich element competitor RNA.

32. (previously presented) The kit of claim 17 wherein the cap-labeled mRNA substrate

comprises Poly(A).

33. (currently amended) The kit of claim 27 32 further comprising means for

+ function

stimulating decapping the cap-labeled mRNA substrate.



34. (currently amended) The kit of claim 27 32 further comprising a cold poly(A)

competitor RNA.

35. (previously presented) The kit of claim 17 wherein the cap-labeled mRNA substrate

comprises an RNA element.

36. (currently amended) The kit of claim 30 35 wherein the RNA element is an AU-

rich element.

37. (currently amended) The kit of claim 31 36 furthering comprising means for

+ function

reducing decapping the cap-labeled mRNA substrate.



38. (currently amended) The kit of claim 31 36 further comprising an ARE AU-rich

element competitor RNA.

**RESPONSE UNDER 37 C.F.R. § 1.116  
EXPEDITED PROCEDURE – Art Unit 1636  
Attorney Docket No. 54569.8009.US01**

39. (currently amended) A mammalian *in vitro* mRNA decapping system comprising:

a) a mammalian polysome-free HeLa cell cytoplasmic extract substantially free of polysomes;

b) a cap-labeled mRNA substrate; and

c) means for decapping the cap-labeled mRNA substrate.

40. (currently amended). A kit for measuring mRNA decapping *in vitro* comprising:

42. (new) The kit of claim 39 wherein the polysome-free HeLa cell cytoplasmic extract is a HeLa S100 cell cytoplasmic extract.

43. (new) The kit of claim 40 wherein the polysome-free HeLa cell cytoplasmic extract is a HeLa S100 cell cytoplasmic extract.